Patents by Inventor Subramanian Marappan
Subramanian Marappan has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20220306573Abstract: Among other things, the present disclosure provides designed oligonucleotides, compositions, and methods of use thereof. In some embodiments, the present disclosure provides technologies useful for reducing levels of transcripts. In some embodiments, the present disclosure provides technologies useful for modulating transcript splicing. In some embodiments, provided technologies can alter splicing of a dystrophin (DMD) transcript. In some embodiments, the present disclosure provides methods for treating diseases, such as Duchenne muscular dystrophy, Becker's muscular dystrophy, etc.Type: ApplicationFiled: April 11, 2019Publication date: September 29, 2022Inventors: Jason Jingxin Zhang, Chandra Vargeese, Naoki Iwamoto, Chikdu Shakti Shivalila, Nayantara Kothari, Ann Fiegen Durbin, Selvi Ramasamy, Pachamuthu Kandasamy, Jayakanthan Kumarasamy, Gopal Reddy Bommineni, Subramanian Marappan, Sethumadhavan Divakaramenon, David Charles Donnell Butler, Genliang Lu, Hailin Yang, Mamoru Shimizu, Prashant Monian
-
Patent number: 11407775Abstract: The present disclosure, among other things, provides technologies for preparing and purifying phosphoramidites for oligonucleotide synthesis.Type: GrantFiled: March 13, 2017Date of Patent: August 9, 2022Assignee: WAVE LIFE SCIENCES LTD.Inventors: David Charles Donnell Butler, Subramanian Marappan, Ik-Hyeon Paik
-
Publication number: 20220186217Abstract: Among other things, the present disclosure provides designed DMD oligonucleotides, compositions, and methods of use thereof. In some embodiments, the present disclosure provides technologies useful for repairing mutant DMD transcripts by skipping exon 51, so that the transcript can be translated into an internally truncated but at least partially functional Dystrophin protein variant. In some embodiments, the present disclosure provides technologies useful for modulating DMD transcript splicing. In some embodiments, provided technologies can alter splicing of a dystrophin (DMD) DMD transcript. In some embodiments, the present disclosure provides methods for treating diseases, such as muscular dystrophy, including but not limited to Duchenne muscular dystrophy, Becker's muscular dystrophy, etc.Type: ApplicationFiled: December 6, 2019Publication date: June 16, 2022Inventors: Jason Jingxin Zhang, Chandra Vargeese, Naoki Iwamoto, Chikdu Shakti Shivalila, Nayantara Kothari, Ann Fiegen Durbin, Selvi Ramasamy, Pachamuthu Kandasamy, Jayakanthan Kumarasamy, Gopal Reddy Bommineni, Subramanian Marappan, Sethumadhavan Divakaramenon, David Charles Donnell Butler, Genliang Lu, Hailin Yang, Mamoru Shimizu, Prashant Monian, Khoa Ngoc Dang Luu
-
Publication number: 20210254062Abstract: Among other things, the present disclosure provides designed DMD oligonucleotides, compositions, and methods of use GC thereof. In some embodiments, the present disclosure provides technologies useful for repairing mutant DMD transcripts by skipping exon 51 or exon 53, so that the transcript can be translated into an internally truncated but at least partially functional Dystrophin protein variant. In some embodiments, the present disclosure provides technologies useful for modulating DMD transcript splicing. In some embodiments, provided technologies can alter splicing of a dystrophin (DMD) DMD transcript. In some embodiments, the present disclosure provides methods for treating diseases, such as muscular dystrophy, including but not limited to Duchenne muscular dystrophy, Becker's muscular dystrophy, etc.Type: ApplicationFiled: May 10, 2019Publication date: August 19, 2021Applicant: WAVE LIFE SCIENCES LTD.Inventors: Jason Jingxin Zhang, Chandra Vargeese, Naoki Iwamoto, Chikdu Shakti Shivalila, Nayantara Kothari, Ann Fiegen Durbin, Selvi Ramasamy, Pachamuthu Kandasamy, Jayakanthan Kumarasamy, Gopal Reddy Bommineni, Subramanian Marappan, Sethumadhavan Divakaramenon, David Charles Donnell Butler, Genliang Lu, Hailin Yang, Mamoru Shimizu, Prashant Monian
-
Publication number: 20210198305Abstract: Among other things, the present disclosure provides designed APOC3 oligonucleotides, compositions, and methods thereof. In some embodiments, provided oligonucleotide compositions provide improved single-stranded RNA interference and/or RNase H-mediated knockdown. Among other things, the present disclosure encompasses the recognition that structural elements of oligonucleotides, such as base sequence, chemical modifications (e.g., modifications of sugar, base, and/or internucleotidic linkages) or patterns thereof, conjugation with additional chemical moieties, and/or stereochemistry [e.g., stereochemistry of backbone chiral centers (chiral internucleotidic linkages)], and/or patterns thereof, can have significant impact on oligonucleotide properties and activities, e.g., RNA interference (RNAi) activity, stability, delivery, etc.Type: ApplicationFiled: June 1, 2018Publication date: July 1, 2021Inventors: Chandra Vargeese, Naoki Iwamoto, David Charles Donnell Butler, Subramanian Marappan, Genliang Lu, Jason Jingxin Zhang, Vinod Vathipadiekal, Maria David Frank-Kamenetsky, Luciano Henrique Apponi, Hanna Maria Wisniewska, Xiayun Cheng, Young Jin Cho
-
Patent number: 11013757Abstract: The present disclosure pertains to the recognition that immune responses mediated by CpG oligonucleotides can be affected by the stereochemistry of modified internucleotidic linkages such as phosphorothioates. In some embodiments, the present disclosure relates to chirally controlled CpG oligonucleotide compositions comprising CpG oligonucleotides comprising multiple modified internucleotidic linkages such as phosphorothioate linkages, wherein the oligonucleotides comprise one or more CpG region motifs having defined stereochemistry patterns of chiral internucleotidic linkages. In some embodiments, CpG oligonucleotides comprising one or more CpG region motifs are capable of agonizing an immune response. In some embodiments, CpG oligonucleotides comprising one or more CpG region motifs are antagonistic. Methods for making and using chirally controlled CpG oligonucleotide compositions are also described.Type: GrantFiled: June 2, 2017Date of Patent: May 25, 2021Assignee: WAVE LIFE SCIENCES LTD.Inventors: Jason Jingxin Zhang, Naoki Iwamoto, Christopher J. Francis, Chandra Vargeese, David Charles Donnell Butler, Sethumadhavan Divakaramenon, Genliang Lu, Subramanian Marappan
-
Publication number: 20210032620Abstract: Among other things, the present disclosure provides oligonucleotides, compositions, and methods thereof. Among other things, the present disclosure encompasses the recognition that structural elements of oligonucleotides, such as base sequence, chemical modifications (e.g., modifications of sugar, base, and/or internucleotidic linkages) or patterns thereof, conjugation with additional chemical moieties, and/or stereochemistry [e.g., stereochemistry of backbone chiral centers (chiral internucleotidic linkages)], and/or patterns thereof, can have significant impact on oligonucleotide properties and activities, e.g., knockdown ability, stability, delivery, etc. In some embodiments, the oligonucleotides decrease the expression, activity and/or level of a C9orf72 gene, including but not limited to, one comprising a repeat expansion, or a gene product thereof.Type: ApplicationFiled: August 7, 2018Publication date: February 4, 2021Inventors: Chandra Vargeese, Zhong Zhong, Naoki Iwamoto, Jason Jingxin Zhang, Jean-Cosme Dodart, Yuanjing Liu, Pachamuthu Kandasamy, Sethumadhavan Divakaramenon, Genliang Lu, Subramanian Marappan
-
Publication number: 20200362337Abstract: Among other things, the present disclosure provides oligonucleotides, compositions, and methods thereof. Among other things, the present disclosure encompasses the recognition that structural elements of oligonucleotides, such as base sequence, chemical modifications (e.g., modifications of sugar, base, and/or internucleotidic linkages) or patterns thereof, conjugation with additional chemical moieties, and/or stereochemistry [e.g., stereochemistry of backbone chiral centers (chiral internucleotidic linkages)], and/or patterns thereof, can have significant impact on oligonucleotide properties and activities, e.g., knockdown ability, stability, delivery, etc. In some embodiments, the oligonucleotides decrease the expression, activity and/or level of a C9orf72 gene, including but not limited to, one comprising a repeat expansion, or a gene product thereof.Type: ApplicationFiled: August 7, 2018Publication date: November 19, 2020Inventors: Jean-Cosme Dodart, Yuanjing Liu, Chandra Vargeese, Zhong Zhong, Naoki Iwamoto, Jason Jingxin Zhang, Pachamuthu Kandasamy, Sethumadhavan Divakaramenon, Genliang Lu, Subramanian Marappan
-
Publication number: 20200190515Abstract: Among other things, the present disclosure provides designed PNPLA3 oligonucleotides, compositions, and methods thereof. In some embodiments, provided oligonucleotide compositions provide improved single-stranded RNA interference and/or RNase H-mediated knockdown. Among other things, the present disclosure encompasses the recognition that structural elements of oligonucleotides, such as base sequence, chemical modifications (e.g., modifications of sugar, base, and/or internucleotidic linkages) or patterns thereof, conjugation with additional chemical moieties, and/or stereochemistry [e.g., stereochemistry of backbone chiral centers (chiral internucleotidic linkages)], and/or patterns thereof, can have significant impact on oligonucleotide properties and activities, e.g., RNA interference (RNAi) activity, stability, delivery, etc.Type: ApplicationFiled: June 1, 2018Publication date: June 18, 2020Inventors: Chandra Vargeese, Naoki Iwamoto, David Charles Donnell Butler, Subramanian Marappan, Genliang Lu, Jason Jingxin Zhang, Vinod Vathipadiekal, Luciano Henrique Apponi, Hanna Maria Wisniewska, Xiayun Cheng, Young Jin Cho
-
Publication number: 20200157545Abstract: Among other things, the present disclosure provides designed oligonucleotides, compositions, and methods thereof. In some embodiments, provided oligonucleotide compositions provide improved single-stranded RNA interference and/or RNase H-mediated knockdown. Among other things, the present disclosure encompasses the recognition that structural elements of oligonucleotides, such as base sequence, chemical modifications (e.g., modifications of sugar, base, and/or internucleotidic linkages) or patterns thereof, conjugation with additional chemical moieties, and/or stereochemistry [e.g., stereochemistry of backbone chiral centers (chiral internucleotidic linkages)], and/or patterns thereof, can have significant impact on oligonucleotide properties and activities, e.g., RNA interference (RNAi) activity, stability, delivery, etc.Type: ApplicationFiled: June 1, 2018Publication date: May 21, 2020Applicants: WAVE LIFE SCIENCES LTD., WAVE LIFE SCIENCES LTD.Inventors: Chandra Vargeese, Naoki Iwamoto, David Charles Donnell Butler, Subramanian Marappan, Genliang Lu, Jason Jingxin Zhang, Vinod Vathipadiekal, Maria David Frank-Kamenetsky, Luciano Henrique Apponi, Young Jin Cho
-
Publication number: 20190390197Abstract: Among other things, the present disclosure relates to designed oligonucleotides, compositions, and methods thereof. In some embodiments, provided oligonucleotide compositions provide altered splicing of a transcript. In some embodiments, provided oligonucleotide compositions have low toxicity. In some embodiments, provided oligonucleotide compositions provide improved protein binding profiles. In some embodiments, provided oligonucleotide compositions have improved delivery. In some embodiments, provided oligonucleotide compositions have improved uptake. In some embodiments, the present disclosure provides methods for treatment of diseases using provided oligonucleotide compositions.Type: ApplicationFiled: October 6, 2017Publication date: December 26, 2019Inventors: David Charles Donnell Butler, Sethumadhavan Divakaramenon, Christopher J. Francis, Maria David Frank-Kamenetsky, Naoki Iwamoto, Genliang Lu, Subramanian Marappan, Meena ., Chandra Vargeese, Gregory L. Verdine, Hailin Yang, Jason Jingxin Zhang
-
Publication number: 20190375774Abstract: The present disclosure, among other things, provides technologies for oligonucleotide synthesis. In some embodiments, the present disclosure provides phosphoramidites and methods for synthesis thereof. In some embodiments, provided methods provides higher yields and/or purities. In some embodiments, provided methods remove byproducts without contact with an aqueous solution.Type: ApplicationFiled: November 22, 2017Publication date: December 12, 2019Inventors: David Charles Donnell Butler, Pachamuthu Kandasamy, Subramanian Marappan, Ik-Hyeon Paik, Jayakanthan Kumarasamy, Gopal Reddy Bommineni
-
Patent number: 10450568Abstract: Among other things, the present disclosure relates to designed oligonucleotides, compositions, and methods thereof. In some embodiments, provided oligonucleotide compositions provide altered splicing of a transcript. In some embodiments, provided oligonucleotide compositions have low toxicity. In some embodiments, provided oligonucleotide compositions provide improved protein binding profiles. In some embodiments, provided oligonucleotide compositions have improved delivery. In some embodiments, provided oligonucleotide compositions have improved uptake. In some embodiments, the present disclosure provides methods for treatment of diseases using provided oligonucleotide compositions.Type: GrantFiled: September 23, 2018Date of Patent: October 22, 2019Assignee: WAVE LIFE SCIENCES LTD.Inventors: David Charles Donnell Butler, Sethumadhavan Divakaramenon, Christopher J. Francis, Maria David Frank-Kamenetsky, Naoki Iwamoto, Genliang Lu, Subramanian Marappan, Meena, Chandra Vargeese, Gregory L. Verdine, Hailin Yang, Jason Jingxin Zhang
-
Publication number: 20190249173Abstract: In some embodiments, the present disclosure pertains to compositions and methods related to delivery of a biologically active agent, wherein the compositions comprise a biologically active agent and a lipid. In various embodiments, the lipid is selected from: lauric acid, myristic acid, palmitic acid, stearic acid, oleic acid, linoleic acid, alpha-linolenic acid, gamma-linolenic acid, docosa-hexaenoic acid (cis-DHA), turbinaric acid and dilinoleyl. In some embodiments, a composition and method are useful for delivery of a biologically active agent to a particular cell or tissue, e.g., a muscle cell or tissue.Type: ApplicationFiled: May 3, 2017Publication date: August 15, 2019Inventors: Chandra Vargeese, Jason Jingxin Zhang, Sethumadhavan Divakaramenon, David Charles Donnell Butler, Genliang Lu, Naoki Iwamoto, Hailin Yang, Maria David Frank-Kamenetsky, Subramanian Marappan
-
Publication number: 20190209604Abstract: The present disclosure pertains to the recognition that immune responses mediated by CpG oligonucleotides can be affected by the stereochemistry of modified internucleotidic linkages such as phosphorothioates. In some embodiments, the present disclosure relates to chirally controlled CpG oligonucleotide compositions comprising CpG oligonucleotides comprising multiple modified internucleotidic linkages such as phosphorothioate linkages, wherein the oligonucleotides comprise one or more CpG region motifs having defined stereochemistry patterns of chiral internucleotidic linkages. In some embodiments, CpG oligonucleotides comprising one or more CpG region motifs are capable of agonizing an immune response. In some embodiments, CpG oligonucleotides comprising one or more CpG region motifs are antagonistic. Methods for making and using chirally controlled CpG oligonucleotide compositions are also described.Type: ApplicationFiled: June 2, 2017Publication date: July 11, 2019Applicant: WAVE LIFE SCIENCES LTD.Inventors: Jason Jingxin Zhang, Naoki Iwamoto, Christopher J. Francis, Chandra Vargeese, David Charles Donnell Butler, Sethumadhavan Divakaramenon, Genliang Lu, Subramanian Marappan
-
Publication number: 20190127733Abstract: Among other things, the present disclosure relates to designed oligonucleotides, compositions, and methods thereof. In some embodiments, provided oligonucleotide compositions provide altered splicing of a transcript. In some embodiments, provided oligonucleotide compositions have low toxicity. In some embodiments, provided oligonucleotide compositions provide improved protein binding profiles. In some embodiments, provided oligonucleotide compositions have improved delivery. In some embodiments, provided oligonucleotide compositions have improved uptake. In some embodiments, the present disclosure provides methods for treatment of diseases using provided oligonucleotide compositions.Type: ApplicationFiled: October 7, 2016Publication date: May 2, 2019Inventors: David Charles Donnell Butler, Sethumadhavan Divakaramenon, Christopher J. Francis, Maria David Frank-Kamenetsky, Naoki Iwamoto, Genliang Lu, Subramanian Marappan, Meena ., Chandra Vargeese, Gregory L. Verdine, Hailin Yang, Jason Jingxin Zhang
-
Publication number: 20190077817Abstract: The present disclosure, among other things, provides technologies for preparing and purifying phosphoramidites for oligonucleotide synthesis.Type: ApplicationFiled: March 13, 2017Publication date: March 14, 2019Inventors: David Charles Donnell Butler, Subramanian Marappan
-
Publication number: 20190008986Abstract: Among other things, the present disclosure relates to designed oligonucleotides, compositions, and methods thereof. In some embodiments, provided oligonucleotide compositions provide altered splicing of a transcript. In some embodiments, provided oligonucleotide compositions have low toxicity. In some embodiments, provided oligonucleotide compositions provide improved protein binding profiles. In some embodiments, provided oligonucleotide compositions have improved delivery. In some embodiments, provided oligonucleotide compositions have improved uptake. In some embodiments, the present disclosure provides methods for treatment of diseases using provided oligonucleotide compositions.Type: ApplicationFiled: September 23, 2018Publication date: January 10, 2019Inventors: David Charles Donnell Butler, Sethumadhavan Divakaramenon, Christopher J. Francis, Maria David Frank-Kamenetsky, Naoki Iwamoto, Genliang Lu, Subramanian Marappan, Meena ., Chandra Vargeese, Gregory L. Verdine, Hailin Yang, Jason Jingxin Zhang
-
Publication number: 20160168636Abstract: The invention generally relates to nucleotide analogs and methods of their use in sequencing-by-synthesis reactions. In certain embodiments, the invention provides a nucleotide analog including a detectable label attached to a nitrogenous base portion of a nucleotide analog by a cleavable linker, in which contact of the analog with at least one activating agent results in cleavage of the label and elimination of the linker, thereby producing a natural nucleotide, a 9-deaza-G, 9-deaza-A, or ?-uridine.Type: ApplicationFiled: October 14, 2015Publication date: June 16, 2016Inventors: Suhaib Siddiqi, J. William Efcavitch, Judith Mitchell, Subramanian Marappan, Jayson Bowers, Mirna Jaroza
-
Patent number: 9163053Abstract: The invention generally relates to nucleotide analogs and methods of their use in sequencing-by-synthesis reactions. In certain embodiments, the invention provides a nucleotide analog including a detectable label attached to a nitrogenous base portion of a nucleotide analog by a cleavable linker, in which contact of the analog with at least one activating agent results in cleavage of the label and elimination of the linker, thereby producing a natural nucleotide, a 9-deaza-G, 9-deaza-A, or ?-uridine.Type: GrantFiled: December 4, 2009Date of Patent: October 20, 2015Assignee: Fluidigm CorporationInventors: Suhaib Siddiqi, J. William Efcavitch, Judith Mitchell, Subramanian Marappan, Jayson Bowers, Mirna Jaroza